Company: HQL
Filing Date: 2025-12-08
Form Type: N-CSR
Source: 0001104659-25-119341
Chunk: 18

Company: abrdn Life Sciences Investors
Filing Date: 2025-12-08
Form: N-CSR
Chunk 18
---
 $3 | Market approach         | Transaction Price(a)      | N/A                | N/A        | Increases      |
|                     |         $1,060,914 | Income Approach         | Discount Rate             
 Implied market volatility 
 Timing of events          
 Marketability Discount    | 3.74% - 3.93%      
 0.48%              
 0.25 - 4.68 years  
 0.75%              | 3.82%      
 0.48%      
 2.79 years 
 0.75%      | Decreases      
 Decreases      
 Decreases      
 Decreases      |
| Other Assets        |               $189 | Income approach         | Discount rate             
 Probability of events     
 Timing of events          | 4.04%              
 5.00%              
 6.25 years         | 4.04%      
 5.00%      
 6.25 years | Decreases      
 Increases      
 Decreases      |
| Total               |        $49,939,305 |                         |                           |                    |            |                |

Amounts listed as “–” are $0 or round to $0.

| (a) | The valuation technique used as a basis to approximate fair value of these investments is based on a transaction price or subsequent financing rounds. |

b. Restricted Securities:

Restricted securities are privately-placed securities whose resale is restricted under U.S. securities laws. The Fund may invest in restricted securities, including unregistered securities eligible for resale without registration pursuant to Rule 144A and privately-placed securities of U.S. and non-U.S. issuers offered outside the U.S. without registration pursuant to Regulation S under the Securities Act of 1933, as amended (the "1933 Act"). Rule 144A securities may be freely traded among certain qualified institutional investors, such as the Fund, but resale of such securities in the U.S. is permitted only in limited circumstances. c. Foreign Currency Translation: Foreign securities, currencies, and other assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate of said currencies against the U.S. Dollar, as of the Valuation Time, as provided by an independent pricing service approved by the Board. Foreign currency amounts are translated into U.S. Dollars on the following basis: (i) fair value of investment securities, other assets and liabilities – at the current daily rates of exchange at the Valuation Time; and (ii) purchases and sales of investment securities